Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2 DOI Creative Commons

Achilleas Livieratos,

Lars Erik Schiro,

Charalambos Gogos

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1444 - 1444

Опубликована: Дек. 22, 2024

Background/Objectives. Research on respiratory virus immunity duration post-vaccination reveals variable outcomes. This study performed a literature review to assess the efficacy and longevity of immune protection against SARS-CoV-2, influenza, syncytial (RSV), with focus immunocompromised populations. Specific objectives included examining humoral cellular responses exploring impact booster doses hybrid extending protection. Methods. A was conducted focusing studies published from January 2014 November 2024. The search targeted adaptive post-vaccination, natural immunity, for RSV. Selection criteria emphasized human populations, outcomes, individuals. PICO framework guided analysis, culminating in detailed 30 studies. Results. SARS-CoV-2 vaccines exhibited robust initial antibody responses, which waned significantly within six months, necessitating frequent boosters. Influenza RSV similarly showed declines though some influenza demonstrated moderate durability. Hybrid arising combined infection vaccination, provided more resilient lasting than vaccination alone, especially emerging variants. Immunocompromised individuals consistently reduced durability across all studied viruses. Challenges include rapid viral mutations, limiting broad current vaccines. Conclusions. Immune varies types patient Frequent boosters are critical optimizing protection, particularly vulnerable groups. findings underscore need adaptable strategies advancements vaccine design counter rapidly mutating pathogens effectively.

Язык: Английский

Postacute sequelae of SARS-CoV-2 in the population: Risk factors and vaccines DOI Creative Commons
Aditi Bhargava, Sabra S. Inslicht

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Март 17, 2025

Abstract The contribution of pre-existing conditions to severe versus mild postacute sequelae (PASC) SARS-CoV-2 in the population is lacking. Here, we evaluated reproductive and other PASC side-by-side unvaccinated vaccinated individuals after 1st infection. In an online global survey 7,541 from 95 countries, high grade fever (> 102˚F)/ hospitalization a first infection were more likely be reported by males than (13.64% vs. 8.34%; p = 0.0483; HR 1.63 [95% CI: 1.008, 2.65]). Women experiencing frequent men. More women men vaccine-associated adverse events (AEs) dose (60.85% vs 48.79%, < 0.01). Vaccine-associated was 6.24% naïve respondents 1.06% Pre-existing thyroid disease, osteoporosis, autoimmune disorders prevalent women, whereas back problems, elevated cholesterol, hypertension; several posed ≥ 2.0 relative risk developing COVID-19. Individuals aged 55 years had absolute 6.01%, 11.69% getting COVID-19 disease. Vaccinated significantly greater menstrual cycle-associated compared women. hormonal changes sexual dysfunction as A detailed thorough follow-up needed better understand if health and/or AEs exacerbated sequelae.

Язык: Английский

Процитировано

0
Impact of pre-Omicron COVID-19 vaccine boosters on the risk of Omicron variant infections: A systematic review and meta-regression DOI Creative Commons

Bing-Yi Pan,

IShin Tseng,

Yen‐Chen Anne Feng

и другие.

Journal of the Formosan Medical Association, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2 DOI Creative Commons

Achilleas Livieratos,

Lars Erik Schiro,

Charalambos Gogos

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1444 - 1444

Опубликована: Дек. 22, 2024

Background/Objectives. Research on respiratory virus immunity duration post-vaccination reveals variable outcomes. This study performed a literature review to assess the efficacy and longevity of immune protection against SARS-CoV-2, influenza, syncytial (RSV), with focus immunocompromised populations. Specific objectives included examining humoral cellular responses exploring impact booster doses hybrid extending protection. Methods. A was conducted focusing studies published from January 2014 November 2024. The search targeted adaptive post-vaccination, natural immunity, for RSV. Selection criteria emphasized human populations, outcomes, individuals. PICO framework guided analysis, culminating in detailed 30 studies. Results. SARS-CoV-2 vaccines exhibited robust initial antibody responses, which waned significantly within six months, necessitating frequent boosters. Influenza RSV similarly showed declines though some influenza demonstrated moderate durability. Hybrid arising combined infection vaccination, provided more resilient lasting than vaccination alone, especially emerging variants. Immunocompromised individuals consistently reduced durability across all studied viruses. Challenges include rapid viral mutations, limiting broad current vaccines. Conclusions. Immune varies types patient Frequent boosters are critical optimizing protection, particularly vulnerable groups. findings underscore need adaptable strategies advancements vaccine design counter rapidly mutating pathogens effectively.

Язык: Английский

Процитировано

0